Arcturus Therapeutics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Arcturus Therapeutics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2019-03-31 |
|---|---|
| operating activities: | |
| net income | -6,884,000 |
| adjustments to reconcile net income to net cash from operating activities: | |
| depreciation and amortization | 172,000 |
| share-based compensation expense | 399,000 |
| non-cash interest expense | 34,000 |
| income from equity-method investment | 288,000 |
| changes in operating assets and liabilities | |
| accounts receivable | 24,000 |
| prepaid expense and other assets | -291,000 |
| accounts payable | 1,586,000 |
| accrued liabilities | -1,891,000 |
| right of use asset and liability | 8,000 |
| deferred revenue | 1,144,000 |
| net cash from operating activities | -5,411,000 |
| capex | -78,000 |
| free cash flows | -5,489,000 |
| investing activities: | |
| proceeds from maturities of short-term investments | |
| purchases of short-term investments | |
| acquisition of property and equipment | -78,000 |
| net cash from investing activities | -78,000 |
| financing activities: | |
| proceeds from exercise of share options | |
| net cash from financing activities | |
| net increase in cash, cash equivalents and restricted cash | -5,489,000 |
| cash, cash equivalents and restricted cash at beginning of the period | 36,816,000 |
| cash, cash equivalents and restricted cash at end of the period | 31,327,000 |
| income from equity method investment | |
| non cash interest expenses | |
| debt conversion expense | |
| changes in operating assets and liabilities: | |
| prepaid expenses and other assets | |
| proceeds from sale of equipment | |
| proceeds from long-term debt, net of debt issuance costs | |
| proceeds from exercise of stock options | |
| proceeds from issuance of convertible promissory notes | |
| proceeds from exercise of warrants | |
| net cash received in the issuance of shares for the net assets of alcobra ltd. | |
| cash, cash equivalents and restricted cash at beginning of year | |
| cash, cash equivalents and restricted cash at end of year | |
| supplemental disclosure of cash flow information: | |
| cash paid for interest | |
| cash paid for income taxes | |
| sale of intangible assets for equity method investment | |
| purchase of property and equipment in accounts payable | |
| release of repurchase liability for restricted shares | |
| conversion of notes to ordinary shares | |
| fair value of assets acquired, excluding cash, cash equivalents and restricted cash | |
| less: liabilities assumed | |
| net assets acquired, excluding cash, cash equivalents and restricted cash |
We provide you with 20 years of cash flow statements for Arcturus Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arcturus Therapeutics stock. Explore the full financial landscape of Arcturus Therapeutics stock with our expertly curated income statements.
The information provided in this report about Arcturus Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.